Capital Royalty L.P. Company Profile

13:00 EDT 23rd March 2018 | BioPortfolio

Our diversified team of investment professionals is dedicated to meeting the specific needs of each client, and with our extensive experience in the healthcare and financial industries, Capital Royalty has the market knowledge and financial know how necessary to help you maximize the value of your royalty interest.


1000 Main, Suite 2500
United States of America


Phone: (713) 209-7350
Fax: (713) 209-7351

News Articles [640 Associated News Articles listed on BioPortfolio]

Albireo sells HealthCare Royalty Partners its elobixibat royalty rights in Japan

Albireo Pharma Inc., through its Elobix subsidiary, entered into an agreement with HealthCare Royalty Partners to monetize its royalty rights for the constipation drug elobixibat in Japan.

Agenus enters $230mm royalty sale agreement with Healthcare Royalty

Immuno-oncology firm Agenus Inc. entered a $230mm royalty sale agreement with Healthcare Royalty Partners, which will pay $190mm in cash up front in exchange for royalties Agenus is eligible to receiv...

Albireo Announces Royalty Monetization Agreement with HealthCare Royalty Partners for Elobixibat in Japan

— Albireo subsidiary eligible to receive up to $60 million under agreement — — Decision on Japanese New Drug Application for elobixibat expected in first half of 2018 — BOSTON, Jan. 03,...

Immunomedics and Royalty Pharma Announce Royalty Funding and Stock Purchase Agreements Totalling $250 Million

Royalty Pharma acquires Royalty Rights on Global Net Sales of Sacituzumab Govitecan (IMMU-132) Across All Indications for $175 Million Royalty Pharma Acquires $75 Million of Immunomedics Common S...

HealthCare Royalty in vaccine royalty deal with Agenus

Albireo in elobixibat royalty deal with HealthCare Royalty

Immunomedics sells sacituzumab royalties to Royalty Pharma

Immunomedics Inc. (monoclonal antibodies for cancer and autoimmune diseases) sold tiered royalty rights for its cancer therapy sacituzumab govitecan (IMMU132) to Royalty Pharma, which paid $175mm cash...

Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2018 -

The Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2018 report is your one-stop source for providing real-deal information on hundreds of transactions, including the technology licen...

PubMed Articles [121 Associated PubMed Articles listed on BioPortfolio]

A Tale of Two Towns: A Comparative Study Exploring the Possibilities and Pitfalls of Social Capital among People Seeking Recovery from Substance Misuse.

Social capital has become an influential concept in debating and understanding the modern world. Within the drug and alcohol sector, the concept of 'recovery capital' has gained traction with research...

Changes in social capital and depressive states of middle-aged adults in Japan.

The present study examines the relationships between changes in bonding and bridging types of social capital and depressive states among middle-aged adults in Japan using a nationally representative s...

Recovery capital pathways: Modelling the components of recovery wellbeing.

In recent years, there has been recognition that recovery is a journey that involves the growth of recovery capital. Thus, recovery capital has become a commonly used term in addiction treatment and r...

The dark side of social capital: A systematic review of the negative health effects of social capital.

There is a growing literature demonstrating the health benefits of social capital (defined as the resources accessed through social connections). However, social capital is also acknowledged to be a "...

Social Capital and Health Among Older Chinese Immigrants: a Cross-Sectional Analysis of a Sample in a Canadian Prairie City.

The objective of this study was to examine the relationship between social capital and health among Chinese immigrants. The sample included 101 older Chinese immigrants aged 60 to 96 who were recruite...

Clinical Trials [38 Associated Clinical Trials listed on BioPortfolio]

Slipped Capital Femoral Epiphysis Treatment

Slipped capital femoral epiphysis represents approximately 10.8 cases per 100,000 children. The primary source for the blood supply of the head of the femur is the deep branch of the media...

The Montreal Neighbourhood Networks and Healthy Aging Panel

Social networks, social capital, i.e., network-accessed resources, and neighbourhood environments have been shown associated with a range of health behaviours and conditions, including obe...

"Gait and Balance in Patients With SCFE"

Slipped Capital Femoral Epiphysis (SCFE) treated with one screw in situ fixation results in an altered gait. It is thought that the protraction of the pelvis at the affected side, seen in ...

Social Inequalities in Emergency Call and Emergency Response Patterns

Background: Inequality in access to healthcare is a challenge internationally. Despite that medical emergency calls can be considered as access point to pre-hospital emergency care and ...

To Develop a Validated Program and Use it to Evaluate Patients Post-operatively

Annually, the Department of Anesthesiology, Siriraj hospital has responsibilities to take care of more than 50,000 patients peri-operatively. According to Maslow's hierarchy of needs; huma...

Companies [1060 Associated Companies listed on BioPortfolio]

Capital Royalty L.P.

Our diversified team of investment professionals is dedicated to meeting the specific needs of each client, and with our extensive experience in the healthcare and financial industries, Capital Royalt...


A pioneer in the field when launched in 1992, Drug Royalty was the first firm to provide royalty-based financing in the life sciences sector and the first to complete royalty transactions with invento...

DRI Capital Inc.

DRI is a pioneer and global leader in healthcare royalty investing and has completed transactions with large global pharmaceutical companies, biotechnology companies, universities...

Drug Royalty

Drug Royalty is an innovative and profitable Canadian company involved in the international life science industry. Established in 1992, DRC was designed to participate in the growth from the global he...

HealthCare Royalty Partners

HealthCare Royalty Partners (HCRP) is a global healthcare investment firm focused on investing primarily in commercial stage healthcare product assets. HCRP manages over $3 billio...

More Information about "Capital Royalty L.P." on BioPortfolio

We have published hundreds of Capital Royalty L.P. news stories on BioPortfolio along with dozens of Capital Royalty L.P. Clinical Trials and PubMed Articles about Capital Royalty L.P. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Capital Royalty L.P. Companies in our database. You can also find out about relevant Capital Royalty L.P. Drugs and Medications on this site too.

Quick Search


Relevant Topic

Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

Corporate Database Quicklinks

Searches Linking to this Company Record